Benefits and risks of adjuvant treatment with zoledronic acid in stage II/III breast cancer. 10 years follow-up of the AZURE randomized clinical trial (BIG 01/04).

Coleman, R E; Collinson, M; Gregory, W; Marshall, H; Bell, R; Dodwell, D; Keane, M; Gil, M; Barrett-Lee, P; Ritchie, D; Bowman, A; Liversedge, V; De Boer, R H; Passos-Coelho, J L; O'Reilly, S; Bertelli, G; Joffe, J; Brown, J E; Wilson, C; Tercero, J C; Jean-Mairet, J; Gomis, R; Cameron, D

Coleman, R E; Collinson, M; Gregory, W; Marshall, H; Bell, R; Dodwell, D; Keane, M; Gil, M; Barrett-Lee, P; Ritchie, D; Bowman, A; Liversedge, V; De Boer, R H; Passos-Coelho, J L; O'Reilly, S; Bertelli, G; Joffe, J; Brown, J E; Wilson, C; Tercero, J C; Jean-Mairet, J; Gomis, R; Cameron, D.

Afiliación

Coleman RE; Academic Unit of Clinical Oncology and Sheffield Experimental Cancer Medicine Center, Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, UK.
Collinson M; Clinical Trials Research Unit, University of Leeds, Leeds, UK.
Gregory W; Clinical Trials Research Unit, University of Leeds, Leeds, UK.
Marshall H; Clinical Trials Research Unit, University of Leeds, Leeds, UK.
Bell R; Andrew Love Cancer Centre, Geelong, Australia.
Dodwell D; St James Institute of Oncology, University of Leeds, UK.
Keane M; University Hospital Galway, Ireland.
Gil M; Institut Català d´Oncologia - IDIBELL. L'Hospitalet de Llobregat, Barcelona, Spain.
Barrett-Lee P; Velindre Cancer Center, Whitchurch, Cardiff, UK.
Ritchie D; Beatson West of Scotland Cancer Centre, Glasgow, UK.
Bowman A; Edinburgh Cancer Research Centre, Western General Hospital, University of Edinburgh, UK.
Liversedge V; Clinical Trials Research Unit, University of Leeds, Leeds, UK.
De Boer RH; Royal Melbourne Hospital, Melbourne, Australia.
Passos-Coelho JL; Hospital da Luz, Lisbon, Portugal.
O'Reilly S; Cork University Hospital, Ireland.
Bertelli G; Sussex Cancer Centre, Brighton, UK.
Joffe J; Huddersfield Royal Infirmary, Huddersfield, UK.
Brown JE; Academic Unit of Clinical Oncology and Sheffield Experimental Cancer Medicine Center, Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, UK.
Wilson C; Academic Unit of Clinical Oncology and Sheffield Experimental Cancer Medicine Center, Weston Park Hospital, University of Sheffield, Sheffield S10 2SJ, UK.
Tercero JC; Inbiomotion SL, Barcelona, Spain.
Jean-Mairet J; Inbiomotion SL, Barcelona, Spain.
Gomis R; Institute for Research in Biomedicine (IRB Barcelona), Barcelona Science and Technology Institute, CIBERONC and Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain.
Cameron D; Edinburgh Cancer Research Centre, Western General Hospital, University of Edinburgh, UK.

J Bone Oncol ; 13: 123-135, 2018 Nov.

Article en En | MEDLINE | ID: mdl-30591866

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Tipo de estudio: Clinical_trials / Etiology_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: J Bone Oncol Año: 2018 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google